Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
180 Life Sciences Corp (ATNF) is a clinical-stage biotechnology company pioneering treatments for inflammatory diseases, fibrosis, and pain through advanced therapeutic platforms. This page serves as the definitive source for official news and developments across the company’s scientific research and blockchain-enabled iGaming initiatives.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, financial announcements, and strategic partnerships. Key focus areas include the company’s anti-TNF fibrosis research, synthetic cannabidiol analogs development, and expansion into blockchain-based gaming technology solutions.
All content is curated to provide accurate, compliance-focused information without speculative commentary. Regular updates ensure stakeholders maintain current awareness of ATNF’s progress in both biotechnology and digital innovation sectors.
Bookmark this page for direct access to press releases, earnings reports, and operational updates from 180 Life Sciences Corp. Check back frequently for the latest developments shaping this innovative dual-sector enterprise.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a grant from the U.K.'s National Institute for Health and Care Research for a feasibility trial exploring anti-TNF therapy to mitigate post-operative delirium in hip fracture patients aged 60 and over. The trial, led by researchers at the University of Oxford, aims to evaluate the effectiveness of anti-TNF therapy during surgery. Jointly funded by the NIHR and 180 Life Sciences, the trial is expected to begin enrollment in early 2023. This collaboration aims to address a critical unmet medical need, considering the high prevalence of post-operative delirium among older patients.
180 Life Sciences Corp. (NASDAQ: ATNF) announced the closing of its registered direct offering, selling 6,132,076 shares and warrants to buy the same number of shares at $1.06 each. The company aims to use the proceeds for research and development and general corporate needs. The warrants are exercisable after six months and will expire in five years. A.G.P./Alliance Global Partners served as the sole placement agent. This offering was made under an effective shelf registration statement filed with the SEC.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a registered direct offering of 6,132,076 shares and warrants to purchase an equal number of shares at $1.06 per share. The expected gross proceeds are approximately $6.5 million, aimed for research, development, and corporate purposes. The offering closes around July 20, 2022, pending customary conditions. A.G.P./Alliance Global Partners is the placement agent. This issuance follows an effective shelf registration statement filed with the SEC.
180 Life Sciences Corp. (NASDAQ: ATNF) provided an update on its clinical development of a novel therapy for early-stage Dupuytren’s disease. The Phase 2b trial, led by Prof. Jagdeep Nanchahal, successfully met its primary endpoint, showing statistically significant results in nodule hardness (p=0.0002) and size (p=0.0025). The MHRA confirmed the appropriateness of statistical methods used, did not require non-clinical data, and noted a favorable safety profile for adalimumab. The company is focusing on gaining marketing approval from regulatory agencies and expanding its clinical trials.
180 Life Sciences Corp. (NASDAQ: ATNF) has received written feedback from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and the U.S. FDA regarding its anti-TNF treatment for early-stage Dupuytren’s disease. The MHRA has advised that no further non-clinical studies are needed, but requires evidence validating clinical endpoints. The FDA criticized the proposed outcome measures as inadequate for efficacy demonstration and suggested a pre-investigational new drug meeting for more guidance. Approximately 12 million people in the U.S. suffer from this degenerative condition.
180 Life Sciences Corp. (NASDAQ: ATNF) announced the initiation of consultations with regulatory agencies in the UK and USA regarding their Phase 2b trial for Dupuytren’s disease treatment. Positive data from the trial, published in The Lancet Rheumatology, suggests a potential for earlier intervention in patients with this progressive condition. The FDA will respond to the company’s briefing materials, shaping future development strategies. Currently, no approved treatments exist for early-stage Dupuytren’s disease, indicating a significant market opportunity for the company.
180 Life Sciences Corp. (NASDAQ: ATNF) announced positive results from its Phase 2b trial for Dupuytren's disease, published in The Lancet Rheumatology. The study achieved its primary endpoint, showing a significant reduction in nodule hardness at 12 months and continued improvement at 18 months post-treatment. Key findings include a decrease in nodule size and high patient compliance (84%). The trial, funded by the Health Innovation Challenge Fund and 180 Life Sciences, suggests that anti-TNF treatment could offer an effective early intervention option for this debilitating condition.
180 Life Sciences Corp. (NASDAQ: ATNF) announced positive final results from its Phase 2b study of anti-TNF treatment for Dupuytren's disease, published in The Lancet Rheumatology. The study achieved its primary endpoint of reduced nodule hardness at 12 months and demonstrated ongoing improvement at 18 months, suggesting durable benefits from treatment. The trial showed a decrease in nodule size and high patient compliance, with no serious adverse events reported. This study supports anti-TNF therapy as a promising early treatment option for Dupuytren's disease, which currently lacks approved therapies.
180 Life Sciences Corp. (NASDAQ: ATNF) has formed a scientific advisory board (SAB) to enhance its clinical development capabilities. The board includes notable experts such as Dr. Raphael Mechoulam and Dr. Kevin Tracey, who will guide the company's focus on inflammatory diseases and pain management. Following recent positive Phase 2b results in Dupuytren’s Contracture, 180 Life Sciences is set to discuss regulatory pathways with the FDA and MHRA. This strategic move aims to strengthen its pipeline and expedite commercialization efforts.
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology firm, addressed shareholders in a letter from CEO Dr. James Woody, acknowledging recent market declines impacting stock prices. The letter highlighted continued confidence in the company's fundamentals following positive Phase 2b trial results for Dupuytren’s Contracture, with anticipated publication in a peer-reviewed journal. The company, targeting a significant market opportunity estimated at $800M, is pursuing regulatory approvals and exploring strategic partnerships. Financial discipline is emphasized to navigate macroeconomic headwinds.
